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Abstract
Background: Noninvasive ventilation (NIV) is used in critically ill patients with acute respiratory failure (ARF) to
avoid endotracheal intubation. However, the impact of NIV use on ARF patient’s outcomes is still unclear. Our
objectives were to evaluate the rate of NIV failure in hypoxemic patients with an arterial carbon dioxide partial
pressure (PaCO2) < 45 mmHg or ≥ 45 mmHg at ICU admission, the predictors of NIV failure, ICU and hospital
length of stay and 28-day mortality.
Methods: Prospective single center cohort study. All consecutive patients admitted to a mixed ICU during a
three-month period who received NIV, except for palliative care purposes, were included in this study.
Demographic data, APACHE II score, cause of ARF, number of patients that received NIV, incidence of NIV failure,
length of ICU, hospital stay and mortality rate were compared between NIV failure and success groups.
Results: Eighty-five from 462 patients (18.4 %) received NIV and 26/85 (30.6 %) required invasive mechanical
ventilation. NIV failure patients were comparatively younger (67 ± 21 vs. 77 ± 14 years; p = 0.031), had lower arterial
bicarbonate (p = 0.005), lower PaCO2 levels (p = 0.032), higher arterial lactate levels (p = 0.046) and APACHE II score
(p = 0.034) compared to NIV success patients. NIV failure occurred in 25.0 % of patients with PaCO2 ≥ 45 mmHg
and in 33.3 % of patients with PaCO2 < 45 mmHg (p = 0.435). NIV failure was associated with an increased risk of
in-hospital death (OR 4.64, 95 % CI 1.52 to 14.18; p = 0.007) and length [median (IQR)] of ICU [12 days (8–31) vs. 2
days (1–4); p < 0.001] and hospital [30 (19–42) vs. 15 (9–33) days; p = 0.010] stay. Predictors of NIV failure included
age (OR 0.96, 95 % CI 0.93 to 0.99; p = 0.007) and APACHE II score (OR 1.13, 95 % CI 1.02 to 1.25; p = 0.018).
Conclusion: NIV failure was associated with an increased risk of in-hospital death, ICU and hospital stay and was
not affected by baseline PaCO2 levels. Patients that failed were comparatively younger and had higher APACHE II
score, suggesting the need for a careful selection of patients that might benefit from NIV. A well-designed study on
the impact of a short monitored NIV trial on outcomes is needed.
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Background
Noninvasive ventilation (NIV) has been established as a
useful and safe method to improve gas exchange for crit-
ically ill patients with different etiologies of acute re-
spiratory failure (ARF) [1, 2]. NIV decreases work of
breathing, improves arterial oxygenation and alveolar
ventilation, prevents the use of invasive mechanical ven-
tilation, reduces the incidence of ventilator associated
pneumonia, decreases the length of intensive care unit
(ICU) stay and mortality mainly due to chronic obstruct-
ive pulmonary disease exacerbations [3, 4] and acute car-
diogenic pulmonary edema [5–8].
Nevertheless, the use of NIV to support other etiologies
of ARF remains controversial [9–11]. The multifactorial
etiology and the heterogeneity of patients classified as
ARF patients may justify different results obtained with
NIV application [12]. The available evidence suggests cau-
tion in the use of NIV in patients with acute hypoxemic
respiratory failure especially in acute respiratory distress
syndrome (ARDS) and community-acquired pneumonia
due to high NIV failure rates [11, 13, 14].
The overall incidence of NIV failure defined by the
need of intubation and invasive mechanical ventilation
reported in the literature can vary widely, approaching
50 % in patients with community-acquired pneumonia
and ARDS [11, 15]. The reasons for NIV failure are most
commonly related to the incapacity to improve oxygen-
ation, inability to correct dyspnea, incapacity to manage
copious secretions, mask discomfort, agitation, anxiety,
hemodynamic instability and progression of ARF [15].
Delayed identification of patients who fail on NIV may
result in late intubation and initiation of invasive mech-
anical ventilation, which have been associated with in-
creased morbidity and mortality [11].
Therefore, it is imperative to identify the variables that
can help predict patients who will fail on NIV as early as
possible, and thus allow a prompt intubation in cases it
will be necessary [11].
Our objective was to evaluate the rate of NIV fail-
ure in hypoxemic patients with an arterial carbon di-
oxide partial pressure (PaCO2) lower than 45 mmHg
or equal to or higher than 45 mmHg at ICU admis-
sion. We also aimed to evaluate the predictors of
NIV failure, intensive care and hospital length of stay,
mortality rate at day 28 and the main complications
associated with NIV.
Methods
Study design and patient selection
This prospective observational single center cohort study
was conducted in a forty-one bed, open mixed ICU of a
tertiary care hospital in São Paulo, Brazil. This study was
approved by the institutional review board of Hospital
Albert Einstein, who waived the need for informed
consent in view of the observational characteristic of the
study (protocol number: 19301213.5.0000.0071).
During a three-month period, all consecutive patients
admitted to the ICU that presented a peripheral oxygen
saturation (SpO2) lower than 90 % despite oxygen deliv-
ered through a Venturi Mask [fraction of inspired oxy-
gen (FiO2) around of 50 %] or by an oxygen bag (FiO2
around 100 %) that received NIV, except for palliative
care purposes, were included in this study [16].
Patients were excluded when they were under eighteen,
had previous tracheostomy, used NIV for palliative care or
presented contraindications to receiving NIV, including
cardiac or respiratory arrest, Glasgow Coma Scale ≤ 10,
severe upper gastrointestinal bleeding, hemodynamic in-
stability, unstable cardiac arrhythmia, facial surgery or
trauma, upper airway obstruction, inability to cooperate
or protect the airway, inability to clear respiratory secre-
tions or high risk for aspiration. The researches followed
the patients and did not interfere in the ICU medical and
multidisciplinary staff decisions.
Protocol of niv use in the ICU
Noninvasive ventilation was applied to patients admitted
to the ICU that presented a SpO2 lower than 90 % des-
pite oxygen delivered through a Venturi Mask (FiO2
around of 50 %) or by an oxygen bag (FiO2 around 100
%) [16]. Noninvasive ventilation was delivered by a total
face mask, secured with head straps, coupled to a BIPAP
Vision™ (Respironics INC®, Pennsylvania, USA). For pa-
tients with a nasogastric tube, a seal connector in the
dome of the mask was used to minimize air leakage.
After the mask was attached to the patient, pressure
support could be increased from 5 up to 20 cm H2O to
obtain an exhaled tidal volume of 6 mL/kg of predicted
body weight, a respiratory rate lower than 30 breaths per
minute, attenuation of respiratory accessory muscle ac-
tivity and achievement of patient’s comfort. Positive end-
expiratory pressure (PEEP) was initiated at 5 cm H2O
and increased in steps of 2 to 3 cm H2O up to 15 cm
H2O until the FiO2 requirement was 60 % or less in pa-
tients with hypoxemic respiratory failure.
All ventilator settings could be re-adjusted by the at-
tending physician and by a chest physiotherapist, based
on the results of continuous oximetry, measurements of
arterial blood gases (specially PaCO2 and pH) and venti-
lator parameters (expiratory tidal volume, respiratory
rate, and mask leakage) as well as on patients’ comfort.
A baseline arterial blood gas analysis was performed
after patient’s stabilization on NIV.
Patients did not usually receive sedatives. If they were
agitated and uncomfortable with the mask, intravenous
morphine or dexmedetomidine was initiated [17]. All
patients were monitored with continuous electrocardiog-
raphy and SpO2. The heads of the beds were kept
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elevated at 30°. Each patient was evaluated periodically
according to the institutional protocol by the attending
physician and by a respiratory physiotherapist in order
to access the possibility to reduce or increase PEEP or
NIV discontinuation/continuation.
NIV success patients were maintained coupled to a
BIPAP vision continuously during a 24-h period. After-
wards, NIV parameters were re-adjusted based on SpO2,
arterial blood gas analysis (specially PaCO2 levels), venti-
lator parameters (expiratory tidal volume, respiratory
rate and mask leakage) and patient’s comfort. When
FiO2 was lower than 50 %, respiratory rate lower than 30
breaths per minute, expiratory tidal volume higher than
5 mL/kg of predicted body weight with a pressure sup-
port lower than 10 cm H2O and PEEP lower than 8 cm
H2O, NIV was discontinued and oxygen ventury mask
of 50 % initiated. If an oxygen ventury mask of 50 % was
well tolerated during a one-hour period, the ventury
mask of 50 % was alternated with NIV (1 h in ventury
mask of 50 % and 3 h in NIV) until the patient could
stay spontaneously breathing. The maximal time allowed
on full NIV support was 24 h. After 24 h on NIV, pa-
tients that could not stay for at least one hour on oxygen
ventury mask was defined dependent on NIV and was
intubated and mechanically ventilated.
Endotracheal intubation
Detection of NIV failure, the decision to intubate patients
and start mechanical ventilation were made by the attend-
ing physician. Patients who failed treatment with NIV
underwent endotracheal intubation with cuffed endo-
tracheal tubes (internal diameter of 7.5 to 8.5 mm) and
were mechanically ventilated (Servo-i; Maquet Critical
Care, Solna, Sweden).
Criteria for endotracheal intubation included failure to
maintain an arterial oxygen partial pressure (PaO2) > 60
mmHg or SpO2 > 90 % with an FiO2 equal to or greater
than 60 %, PaCO2 higher than 60 mmHg with pH lower
than 7.25, inability to protect the airways or to manage
copious tracheal secretions, hemodynamic or electrocar-
diographic instability, inability to tolerate the face mask,
inability to correct dyspnea and progression of respira-
tory failure [16].
Outcome measures
Demographic data, etiology of respiratory failure, APA-
CHE II score [18], vital signs, electrolytes, hemoglobin,
platelets, white blood cell count, serum creatinine, arter-
ial lactate, FiO2, ratio of the arterial oxygen partial pres-
sure to the fraction of inspired oxygen (PaO2/FiO2),
arterial pH, PaCO2, arterial lactate, number of patients
that used NIV, number of patients that needed endo-
tracheal intubation (NIV failure), in-hospital mortality
rate, mortality at day 28, length of ICU and hospital stay
and complications related to NIV were recorded.
Our primary outcome was the incidence of NIV fail-
ure, defined by the need of endotracheal intubation and
mechanical ventilation in hypoxemic patients with
PaCO2 < 45 mmHg and ≥ 45 mmHg at ICU admission.
Secondary outcomes were the main indications for acute
application of NIV, the predictors of NIV failure, ICU
and hospital lengths of stay, in-hospital and mortality at
day 28 and the main complications associated with non-
invasive ventilation.
Statistical analysis
Categorical variables were displayed as absolute and
relative frequencies. Numerical variables were presented
as mean and standard deviation (SD) or median with
interquartile ranges (IQR) in case of non-normal distri-
bution, tested by the Kolmogorov-Smirnov test.
Comparisons were made between NIV failure and NIV
success groups and between patients with PaCO2 < 45
mmHg and ≥ 45 mmHg at ICU admission. Categorical var-
iables were compared with chi-square test or with Fisher
exact test when appropriate. Continuous variables were
compared using independent t test or Mann–Whitney U
test in case of non-normal distribution. Survival curves at
day 28 were performed according to the Kaplan-Meier
method and compared with a log-rank test.
A univariate logistic regression analysis was performed
to identify which factors (predictors) were associated with
NIV failure. Only variables presented in more than five pa-
tients in each group were included. A multivariate logistic
regression analysis with backward elimination procedure
including all predictors showing a p value ≤ 0.25 in the
univariate analysis was undertaken to obtain an adjusted
odds ratio (OR) with 95 % confidence interval (CI) and de-
fine which variables were independently associated with
NIV failure.
Statistical tests were 2-sided, and a p < 0.05 was con-
sidered statistically significant. Statistical analyses were




In a three-month period, 462 patients were admitted to
the ICU. Ninety-one patients fulfilled the criteria for
NIV use, but six patients were excluded because they
used NIV for palliative care purposes. Therefore, eighty-
five patients were included in the study (Fig. 1).
The baseline characteristics, clinical, physiological and
laboratorial parameters of studied patients are presented
on Table 1. NIV failure patients were comparatively
younger, had lower arterial bicarbonate, and lower
PaCO2 levels and had higher arterial lactate levels and
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APACHE II score compared to NIV success patients
(Table 1). The main etiologies of acute respiratory failure
did not differ between the two groups (Table 2). Con-
cerning comorbidities, NIV failure group had a higher
number of transplanted patients in comparison to NIV
success group (Table 1).
Response to NIV and complications
NIV success occurred in 69.4 % (59/85) of patients (NIV
Success Group) and NIV failure occurred in 30.6 % (26/85)
of patients that needed intubation and mechanical ventila-
tion (NIV failure Group) (Table 1 and Fig. 1). NIV failure
occurred in 25.0 % (7/28) of patients with PaCO2 ≥ 45
mmHg and in 33.3 % (19/57) of patients with PaCO2 < 45
mmHg (OR 0.67, 95 % CI 0.24 to 1.84; p = 0.435) (Table 1).
In 61.5 % (16/26) of patients, NIV failure occurred dur-
ing the first 24 h of noninvasive mechanical ventilation.
The main reasons for endotracheal intubation included
progression of hypoxemia in 65.4 % (17/26), neurological
deterioration in 19.2 % (5/26), gastric distension 7.7 % (2/
26), hemodynamic instability 3.8 % (1/26) and patients’
dangerous agitation 3.8 % (1/26) (Table 2).
The only complication associated with NIV was gastric
distension reported in 3/26 (11.5 %) NIV failure patients
vs. 4/59 (6.8 %) in NIV success groups (p = 0.670;
Table 3).
Length of ICU and hospital stay
The median lengths of ICU and hospital stays were sig-
nificantly higher in NIV failure in comparison to the
NIV success groups (Table 3). The median (IQR) length
of ICU stay [2 (1–8) vs. 4 (2–10), respectively for PaCO2 ≥
45 mmHg and < 45 mmHg; p = 0.101] and hospital stay
[19 (9–30) vs. 21 (12–37), respectively for PaCO2 ≥ 45
mmHg and < 45 mmHg; p = 0.165] were not affected by
baseline PaCO2 levels.
Mortality
In-hospital mortality rate was higher in the NIV failure
patients compared to the NIV success patients [10/26
(38.5 %) vs. 7/59 (11.9 %), respectively for NIV failure and
NIV success groups; p = 0.008] (Table 3). NIV failure was
associated with an increased risk of in-hospital death (OR
4.64, 95 % CI 1.52 to 14.18; p = 0.007) while mortality at
day 28 [5/26 (19.2 %) vs. 4/59 (6.8 %), respectively for NIV
failure and NIV success groups; p = 0.124] did not differ
between NIV failure and success groups (Table 3 and
Figure 2).
In-hospital mortality [3/28 patients (10.7 %) vs. 14/57
patients (24.6 %), respectively for PaCO2 ≥ 45 mmHg
and < 45 mmHg; p = 0.160] and 28-day mortality [3/28
patients (10.7 %) vs. 6/57 patients (10.5 %), respectively
for PaCO2 ≥ 45 mmHg and < 45 mmHg, p = 1.000] did
not differ between patients with baseline PaCO2 ≥ 45
mmHg or < 45 mmHg.
Predictors of NIV failure
From the initial model containing 10 predictors, the back-
ward elimination procedure yielded a reduced model con-
taining age (OR 0.96, 95 % CI 0.93 to 0.99; p = 0.007)
and APACHE II score (OR 1.13, 95 % CI 1.02 to
1.25; p = 0.018) (Table 4). Interaction between age
and APACHE II score was not significant (p = 0.11).
Discussion
This study showed a success rate of approximately
70 % of noninvasive ventilation in a general ICU
population with acute hypoxemic respiratory failure.
The initial PaCO2 levels (<45 mmHg or ≥ 45 mmHg)
was not related to NIV failure/success. Patients who
failed on NIV and received invasive mechanical ventila-
tion were sicker, comparatively younger, had higher ICU
and hospital length of stay and had higher in-hospital
mortality rate. The multivariate logistic regression ana-
lysis showed that APACHE II score was an independent
predictor of NIV failure, suggesting that sicker patients
should be carefully monitored during the NIV trial
regarding heart rate, mean arterial blood pressure and
arterial lactate levels besides monitoring SpO2, PaO2,
PaCO2, pH, respiratory rate and tidal volume for early
prediction of NIV failure.
The main evidence-based clinical indications for
NIV use in the critical care setting are exacerbations
of chronic obstructive pulmonary disease [3, 4] and
acute cardiogenic pulmonary edema [5–8]. Nevertheless,
Fig. 1 Study flow diagram. NIV = noninvasive ventilation, * = p value
comparing in-hospital mortality between NIV failure vs. NIV
success Groups
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advances in NIV ventilators, development of more com-
fortable interfaces, improvement in patients monitoring
and care during NIV delivery and staff training have
contributed to the dissemination of NIV application in
patients with ARF of different etiologies [19–21] and
increased NIV use [20].
The success rate of NIV in critically ill patients can
vary widely [1–11]. The main factors associated with
success or failure were the etiology of respiratory insuffi-
ciency and the presence of dysfunction of other organs
besides the lungs [2]. The reported success of NIV
in hypoxemic respiratory failure is around 50 %
while in hypercapnic respiratory failure it is around
75 % [2]. In our study population, 67 % (57/85) of
patients had PaCO2 < 45 mmHg at baseline and the
main reason for NIV start was desaturation while






Age (years) 67 (21) 77 (14) 0.031a
Male gender, n° (%) 17 (65.4) 27 (45.8) 0.106b
Mean arterial pressure (mmHg) 81 (24) 93 (21) 0.032a
Heart rate (beats/min) 107 (25) 95 (19) 0.031a
APACHE II score 16.0 (4.7) 13.4 (5.3) 0.034a
Arterial pH 7.36 (0.08) 7.39 (0.07) 0.106a
Bicarbonate (mmol/L) 19.6 (7.3) 23.7 (4.7) 0.005a
PaCO2 (mmHg), median [IQR] 30.8 [26.6–40.1] 35.3 [31.5–43.5] 0.032
c
PaCO2 ≥ 45 mmHg, n° (%) 7 (26.9) 21 (35.6) 0.466
b
PaO2/FiO2 277 (148) 282 (109) 0.878
a
Arterial lactate (mg/dl), median [IQR] 17 [14–26] 12 [8–21] 0.046c
Hemoglobin (mg/dl) 10.6 (2.1) 11.0 (2.1) 0.499a
Reason for ICU admission, n° (%)
Medical 20 (76.9) 53 (89.8) 0.174b
Operative 6 (23.1) 6 (10.2)
Comorbidities, n (%)
Diabetes Mellitus 9 (34.6) 15 (25.4) 0.438b
Transplantation 7 (26.9) 2 (3.4) 0.003b
Chronic renal failure 6 (23.1) 8 (13.6) 0.344b
Systemic hypertension 6 (23.1) 17 (28.8) 0.792b
COPD 6 (23.1) 12 (20.3) 0.779b
Liver cirrhosis 4 (15.4) 1 (1.7) 0.029b
Coronary insufficiency 4 (15.4) 12 (20.3) 0.766b
Congestive heart failure 4 (15.4) 22 (37.3) 0.072b
Neoplasm 3 (11.5) 7 (11.9) 1.000b
None 2 (7.7) 12 (20.3) 0.209b
Values are mean (SD) or median [IQR] when indicated
¶ = p values and the respective statistical tests comparing NIV failure vs. NIV success groups. a = Independent t-test, b = Fisher’s exact test, c = Mann–Whitney U
test. APACHE II Acute physiology and chronic health evaluation II (The score can range from 0 to 71, with higher scores indicating more severe illness), PaCO2
Partial pressure of arterial carbon dioxide, and PaO2/FiO2 Ratio of the arterial oxygen partial pressure to the fraction of inspired oxygen, ICU Intensive care unit,
COPD Chronic obstructive pulmonary disease
Table 2 Main causes of acute respiratory failure





Community acquired pneumonia 10 (38.5) 20 (33.9) 0.806
Cardiogenic pulmonary edema 4 (15.4) 15 (25.4) 0.402
Acute respiratory distress syndrome 5 (19.2) 5 (8.5) 0.271
Acute COPD 3 (11.5) 7 (11.9) 1.000
Other causes of ARFa 4 (15.4) 12 (20.3) 0.766
¶ = p values with Fisher’s exact test comparing NIV failure vs. NIV success groups.
COPD Chronic obstructive pulmonary disease, a = mucous plugging, atelectasis,
pulmonary embolism, pulmonary contusion and neuromuscular disease
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receiving supplementary oxygen through a Venturi
mask or oxygen bag. The success of NIV in this
group was approximately 67 % (38/57 patients),
which shows that in everyday clinical practice, NIV
should be attempted in the hypoxemic respiratory
failure with two thirds of success without major
complications when observing the use of an appro-
priate interface and NIV ventilator.
In our study, acute respiratory failure caused by
community-acquired pneumonia was the main reason
for NIV use. Intubation was avoided in 67 % (20/30) of
the patients. Our results are in accordance to a recent
report on the use of NIV in severe community-acquired
pneumonia with acute respiratory failure that observed
NIV success in 95 out of 127 (75 %) patients, suggesting
that NIV should be a good option for patients with acute
respiratory failure secondary to a community-acquired
pneumonia [22].
Results in the medical literature suggest that NIV use
in ARDS patients must be attempted with caution, due
to high need of intubation and mortality rates associated
with failure in these patients, especially in the more se-
vere ones [23]. Recently, the use of NIV for acute hypox-
emic failure was assessed in 82 ARDS and 31 non-ARDS
patients over a 3-year period in an prospective cohort
study [24]. Intubation rate was significantly higher in
ARDS in comparison to non-ARDS patients (61 % vs.
35 %, p = 0.015) and varied according to the severity
of disease: 31 % in mild, 62 % in moderate, and 84 % in se-
vere ARDS (p = 0.0016) [24]. NIV failure was lower
among moderate ARDS patients having a PaO2/FiO2 >
150 mmHg (45 % vs. 74 %, p = 0.04) [24].
Antonelli and colleagues showed in a randomized mul-
ticenter study that NIV was able to enhance oxygenation
and avoid intubation in 54 % of ARDS patients [25].
Avoidance of intubation resulted in reduction of
ventilator-associated pneumonia, ICU length of stay and
mortality [25]. In our study, only 10 of our patients had
the diagnosis of ARDS with a NIV success rate of 50 %.
The median (IQR) length of ICU stay was 3.0 (3.0–5.0)
days for ARDS patients treated successfully with NIV
and 18.0 (10.0–34.0) days for those who required inva-
sive mechanical ventilation (p = 0.008) although the in-
hospital mortality did not differ between ARDS patients
who failed on NIV in comparison to NIV success pa-
tients [3/5 (60 %) vs. 0/5 (0 %), p = 0.167]. According to
these findings, instead of caution or contraindication of
NIV use in ARDS patients, we suggest that a monitored
ICU NIV trial should be considered in the ARDS pa-
tients due to the low mortality rates when NIV is suc-
cessfully delivered [26]. However, in patients who failed
the NIV trial, prompt intubation and invasive mechan-
ical ventilation must be provided due to related high
mortality rates in this population [26].
We found a higher prevalence of transplanted patients
in the NIV failure group than in the NIV success group.
A significant reduction in intubation rate and ICU
length of stay using NIV for respiratory failure in recipi-
ents of solid organ transplantation have been reported
[27–29]. Contrary to these findings, we observed a
higher incidence of NIV failure in transplanted patients
[7/9 (77.7 %)]. In our study, transplanted patients were
comparatively younger than non-transplanted patients
(45 ± 15 vs. 77 ± 13 years, respectively, p < 0.001). The
younger age and higher failure rate in the transplanted
patients may have contributed to the finding that com-
paratively younger age (67 ± 21 vs. 77 ± 14) was an inde-
pendent predictor of NIV failure in our study.
In the present study, in-hospital mortality rate was
higher in the NIV failure patients compared to the NIV
success patients. Recently, Schnell and colleagues analyzed
1232 patients that received NIV out of 3163 (39 %) critic-
ally ill patients from a multicenter database [30]. First-line
NIV was associated with better 60-day survival and fewer
Table 3 Mortality rate, length of stay and incidence of







Length of ICU stay (days) 12 [8–31] 2 [1–4] <0.001a
Length of hospital stay (days) 30 [19–42] 15 [9–33] 0.010a
Mortality at day 28, n° (%) 5 (19.2) 4 (6.8) 0.124b
In-hospital mortality, n° (%) 10 (38.5) 7 (11.9) 0.008b
Complications associated with NIV
Gastric distension 3 (11.5) 4 (6.8) 0.670b
¶ = p values for NIV failure vs. NIV success Groups. a = Mann–Whitney U test,
b = Fisher’s exact test and. ICU Intensive care unit. Values are median [IQR] or
n° (%) when indicated
Fig. 2 Kaplan-Meier curve for 28-day survival. NIV = noninvasive
ventilation
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ICU-acquired infections compared to first line intubation
in patients with acute-on-chronic respiratory failure [30].
Furthermore, it has been demonstrated that critically
ill patients who required endotracheal intubation and in-
vasive mechanical ventilation following a noninvasive
ventilation exhibited a higher mortality rate than pa-
tients who were directly intubated [31–33]. Conversely,
due to the increased risk of death attributed to NIV fail-
ure, a short period of NIV trial in hypoxemic respiratory
patients has been proposed [34]. Nevertheless, the dur-
ation of the test and what specific population of hypox-
emic patients this test should be applied in, is not well
established in the literature. While a short period of a
NIV trial may not be enough to allow the effects of NIV
to be detectable, long periods on NIV may be associated
with delayed initiation of mechanical ventilation and,
therefore, to worst outcomes [31]. Therefore, a well-
designed prospective controlled trial comparing a short
well-monitored NIV trial to first line invasive mechanical
ventilation in hypoxemic respiratory failure patients
(excluding patients with absolute contra-indication or
urgent need of intubation) is still needed.
Our study has limitations. This was an observational,
prospective, single center study carried out in a general
medical-surgical ICU for a strict period of three months
and it included a small number of patients. Although
our ICU has a protocol for the management of noninva-
sive ventilation, the identification of NIV failure and the
indication for endotracheal intubation was based on the
judgment of the attending physician. This variability in
the day-by-day ICU medical care decisions is part of our
real world and should be considered in mechanical ven-
tilation studies. Finally, patients were ventilated with a
full-face mask coupled to a BIPAP Vision® (ventilator
specially designed for NIV delivery) that limits the inter-
pretation of our results only to these settings.
Conclusion
In our prospective cohort study, NIV failure in patients
with acute respiratory failure was associated with increased
in-hospital mortality, ICU and hospital stay and was not af-
fected by baseline PaCO2 levels. Patients that failed were
comparatively younger and had higher APACHE II score,
suggesting the need for a careful selection of patients that
might benefit from NIV and the need for a close monitor-
ing in the more severe patients during NIV.
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Table 4 Logistic regression analysis addressing the main risk factors for noninvasive positive pressure ventilation failure
Univariate analysis Multivariate analysis
Risk factors (predictors) OR 95 % CI P value OR 95 % CI P value
Age (years) 0.97 0.94–0.99 0.015 0.96 0.93–0.99 0.007
Male gender 2.24 0.86–5.83 0.100
Mean arterial pressure (mmHg) 0.98 0.95–1.00 0.037
Heart rate (bpm) 1.02 1.00–1.05 0.037
APACHE II score 1.10 1.00–1.21 0.039 1.13 1.02–1.25 0.018
Arterial pH 0.95 0.89–1.01 0.116
Bicarbonate (mmol/L) 0.87 0.78–0.97 0.009
Arterial lactate (mg/dL) 1.05 0.99–1.10 0.081
Transplantation 10.50 2.00–54.95 0.005
Acute respiratory distress syndrome 2.57 0.68–9.80 0.167
OR Odds ratio, CI Confidence interval, APACHE II Acute physiology and chronic health evaluation II (The score can range from 0 to 71, with higher scores
indicating more severe illness)
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